Abstract

Natural chalcones possess antitumor properties and play a role as inducers of apoptosis, antioxidants and cytotoxic compounds. We recently reported that novel nitrogen chalcone-based compounds, which were generated in our lab, have specific effects on triple-negative breast cancer cells. However, the outcome of these two new compounds on human epidermal growth factor receptor 2 (HER2)-positive breast cancer remains nascent. Thus, we herein investigated the effects of these compounds (DK-13 and DK-14) on two HER2-positive breast cancer cell lines, SKBR3 and ZR75. Our data revealed that these compounds inhibit cell proliferation, deregulate cell-cycle progression and significantly induce cell apoptosis in both cell lines. Furthermore, the two chalcone compounds cause a significant reduction in the cell invasion ability of SKBR3 and ZR75 cancer cells. In parallel, we found that DK-13 and DK-14 inhibit colony formation of both cell lines in comparison to their matched controls. On the other hand, we noticed that these two compounds can inhibit angiogenesis in the chorioallantoic membrane model. The molecular pathway analysis of chalcone compounds exposed cells revealed that these compounds inhibit the expression of both JNK1/2/3 and ERK1/2, the major plausible molecular pathways behind these events. Our findings implicate that DK-13 and DK-14 possess effective chemotherapeutic outcomes against HER2-positive breast cancer via the ERK1/2 and JNK1/2/3 signaling pathways.

Highlights

  • Breast cancer is one of the most significant public health impediments among females in the modern world and comprises about 25% of all cancer cases [1]

  • We recently reported that the chalcone-based compounds DK-13 and DK-14, developed by our group, impair the growth of triple-negative breast cancer [24]; we explore the outcome of these two new compounds on two human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell lines in addition to angiogenesis of the chorioallantoic membrane (CAM) model and their underlying mode of action

  • The DK-13 and 14 chalcone compounds, which were recently developed by our group, were evaluated for their antitumor activities on the HER2-positive breast cancer cell lines SKBR3 and ZR75 after 48 h of treatment

Read more

Summary

Introduction

Breast cancer is one of the most significant public health impediments among females in the modern world and comprises about 25% of all cancer cases [1]. Based on gene expression patterns and hierarchical clustering, breast cancer is categorized into five molecular subtypes: Luminal (A and B), human epidermal growth factor receptor 2 (HER2), triple-negative and normal breast-like [2]. The luminal subtypes are hormone receptor (estrogen and progesterone)-positive and HER2 receptor-negative or -positive; while the HER2 subtype overexpresses the HER2 receptor and lacks hormone receptors [2,3]. The triple-negative breast cancer subtype lacks receptors for estrogen, progesterone or HER2 [2,3]. Approximately 20% of the total breast cancer cases are HER2positive, where the tumors overexpress the human epidermal growth factor receptor type 2 (HER2) [4,5] and confer an aggressive tumor phenotype with a poor prognosis [6]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call